← All trials
NCT05615818
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 18, 2024
- Primary completion
- Jun 30, 2027
- Completion date
- Jun 30, 2028
- First posted
- Nov 14, 2022
- Last posted
- Nov 26, 2024
- Enrollment
- 800
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- UNICANCERLead sponsor
- Accord ResearchCollaborator
- Belgian Group of Digestive OncologyCollaborator
- Cancer Research UKCollaborator
- Cancer Research UKCollaborator
- Center Eugene MarquisOfficial
- Université catholique de LouvainOfficial
- Institut Mutualiste MontsourisOfficial
- National Cancer Institute, FranceCollaborator
- Pierre FabreCollaborator
- ServierCollaborator
- OtsukaCollaborator
- Zymeworks Inc.Collaborator
- University of LondonOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.